These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 24401241)

  • 1. Reversal of atherosclerosis with apolipoprotein A1: back to basics.
    Smits LP; Kootte RS; Stroes ES
    Atherosclerosis; 2014 Jan; 232(1):217-9. PubMed ID: 24401241
    [No Abstract]   [Full Text] [Related]  

  • 2. CER-001, a HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice.
    Tardy C; Goffinet M; Boubekeur N; Ackermann R; Sy G; Bluteau A; Cholez G; Keyserling C; Lalwani N; Paolini JF; Dasseux JL; Barbaras R; Baron R
    Atherosclerosis; 2014 Jan; 232(1):110-8. PubMed ID: 24401224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trimerized apolipoprotein A-I (TripA) forms lipoproteins, activates lecithin: cholesterol acyltransferase, elicits lipid efflux, and is transported through aortic endothelial cells.
    Ohnsorg PM; Mary JL; Rohrer L; Pech M; Fingerle J; von Eckardstein A
    Biochim Biophys Acta; 2011 Dec; 1811(12):1115-23. PubMed ID: 21930241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HDL Mimetics Infusion and Regression of Atherosclerosis: Is It Still Considered a Valid Therapeutic Option?
    Karalis I; Jukema JW
    Curr Cardiol Rep; 2018 Jun; 20(8):66. PubMed ID: 29926215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-Density Lipoprotein Mimetics: a Therapeutic Tool for Atherosclerotic Diseases.
    Ikenaga M; Higaki Y; Saku K; Uehara Y
    J Atheroscler Thromb; 2016; 23(4):385-94. PubMed ID: 26830201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis.
    Hennuyer N; Duplan I; Paquet C; Vanhoutte J; Woitrain E; Touche V; Colin S; Vallez E; Lestavel S; Lefebvre P; Staels B
    Atherosclerosis; 2016 Jun; 249():200-8. PubMed ID: 27108950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Role of apolipoprotein AI on nascent high-density lipoprotein particle formation].
    Wu JF; Tang YY; Zeng GF; Tang CK
    Sheng Li Ke Xue Jin Zhan; 2014 Apr; 45(2):81-6. PubMed ID: 25069300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apolipoprotein A-I and its mimetics for the treatment of atherosclerosis.
    Smith JD
    Curr Opin Investig Drugs; 2010 Sep; 11(9):989-96. PubMed ID: 20730693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structures of apolipoprotein A-I in high density lipoprotein generated by electron microscopy and biased simulations.
    Zhu L; Petrlova J; Gysbers P; Hebert H; Wallin S; Jegerschöld C; Lagerstedt JO
    Biochim Biophys Acta Gen Subj; 2017 Nov; 1861(11 Pt A):2726-2738. PubMed ID: 28754383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ApoA-I Milano/phospholipid complexes emerging pharmacological strategies and medications for the prevention of atherosclerotic plaque progression.
    Kaul S; Shah PK
    Curr Drug Targets Cardiovasc Haematol Disord; 2005 Dec; 5(6):471-9. PubMed ID: 16503867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural human apoA-I mutations L141RPisa and L159RFIN alter HDL structure and functionality and promote atherosclerosis development in mice.
    Tiniakou I; Kanaki Z; Georgopoulos S; Chroni A; Van Eck M; Fotakis P; Zannis VI; Kardassis D
    Atherosclerosis; 2015 Nov; 243(1):77-85. PubMed ID: 26363436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation.
    Moore RE; Navab M; Millar JS; Zimetti F; Hama S; Rothblat GH; Rader DJ
    Circ Res; 2005 Oct; 97(8):763-71. PubMed ID: 16151025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A selective peroxisome proliferator-activated receptor δ agonist PYPEP suppresses atherosclerosis in association with improvement of the serum lipoprotein profiles in human apolipoprotein B100 and cholesteryl ester transfer protein double transgenic mice.
    Naya N; Fukao K; Nakamura A; Hamada T; Sugimoto M; Kojima M; Yoshimura N; Uwabe K; Imagawa K; Nomura K; Hara S; Nakano T; Iwasaki T; Shinosaki T; Hanasaki K
    Metabolism; 2016 Jan; 65(1):16-25. PubMed ID: 26683793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice.
    Navab M; Anantharamaiah GM; Reddy ST; Hama S; Hough G; Grijalva VR; Wagner AC; Frank JS; Datta G; Garber D; Fogelman AM
    Circulation; 2004 Jun; 109(25):3215-20. PubMed ID: 15197147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deletion of amino acids Glu146-->Arg160 in human apolipoprotein A-I (ApoA-ISeattle) alters lecithin:cholesterol acyltransferase activity and recruitment of cell phospholipid.
    Lindholm EM; Bielicki JK; Curtiss LK; Rubin EM; Forte TM
    Biochemistry; 1998 Apr; 37(14):4863-8. PubMed ID: 9538003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid-free Apolipoprotein A-I Structure: Insights into HDL Formation and Atherosclerosis Development.
    Mei X; Atkinson D
    Arch Med Res; 2015 Jul; 46(5):351-60. PubMed ID: 26048453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural studies of discoidal lipoprotein A-I.
    Koppaka V
    Cell Mol Life Sci; 2001 Jun; 58(7):885-93. PubMed ID: 11497237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Advances in apolipoprotein A- I and it's anti-atherosclerosis properties].
    Li M; Liu ZM
    Sheng Wu Gong Cheng Xue Bao; 2003 Jul; 19(4):387-91. PubMed ID: 15969051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology of apolipoprotein A-I.
    Andersson LO
    Curr Opin Lipidol; 1997 Aug; 8(4):225-8. PubMed ID: 9253539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecules that mimic apolipoprotein A-I: potential agents for treating atherosclerosis.
    Leman LJ; Maryanoff BE; Ghadiri MR
    J Med Chem; 2014 Mar; 57(6):2169-96. PubMed ID: 24168751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.